Innovation in drug research and development for prevalent chronic diseases proceedings of a workshop
Investment and innovation in drug research and development (R&D) for highly prevalent chronic diseases has stalled in recent decades, despite half of all Americans living with at least one chronic disease. As a result, prevalent chronic diseases are producing immense health care costs as well as...
| Main Author: | |
|---|---|
| Corporate Authors: | , |
| Other Authors: | , , |
| Format: | eBook |
| Language: | English |
| Published: |
Washington, DC
The National Academies Press
2021, [2021]
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Investment and innovation in drug research and development (R&D) for highly prevalent chronic diseases has stalled in recent decades, despite half of all Americans living with at least one chronic disease. As a result, prevalent chronic diseases are producing immense health care costs as well as preventable suffering and death. On February 22, March 2, and March 8, 2021, the National Academies of Sciences, Engineering, and Medicine, convened a workshop to discuss barriers to innovation in this space and examine strategies and incentives to support equitable, person-centered drug R&D for prevalent chronic diseases |
|---|---|
| Physical Description: | 1 PDF file (xv, 96 pages) illustrations |
| ISBN: | 0309092140 9780309092142 |